Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS: Liposomal Irinotecan + 5-FU/LV + Bevacizumab in 2L mCRC
NCT06184698Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in colorectal cancer (CRC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Objective Response Rate at 4 months. Started Jan 2024; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06184698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184698.